BLUE BELL, Pa., July 8, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of its influenza DNA vaccine against the virulent, newly emergent H7N9 flu virus, 100% of the vaccinated animals were protected against sickness and death when they were challenged with a lethal dose of H7N9 virus. The results from a study in mice demonstrated that Inovio's vaccine generated not only hemagglutination inhibition (HAI)-based protection against the H7N9 virus but also strong T-cell responses. Inovio's DNA vaccine created cellular immune responses that could reduce the severity of the infection in a person that acquires the virus and limit the spread of the virus in a pandemic setting. Detailed study results will be presented at an invited plenary session at the TEPIK/APACI International Influenza Symposium being held in Seoul, South Korea, on July 12, 2013. Inovio researchers constructed a consensus DNA vaccine targeting the HA influenza antigen based on sequences collected from several infected H7N9 patients to create a vaccine that is broadly protective against all H7N9 strains. Inovio's vaccine was administered in mice using its proprietary electroporation-based delivery technology twice, 3 weeks apart; the mice were then exposed to a lethal dose of A/ Anhui/1/13 strain of H7N9 virus 4 weeks after the second vaccination. The challenge studies were conducted by Inovio's collaborators at Canada's National Microbiology Laboratory in Winnipeg. Results demonstrated that 100% of the vaccinated animals (n=10) remained healthy without any weight loss (a key indicator of health) and survived while all unvaccinated mice in the control group (n=10) had significant morbidity, including up to 30% weight loss, and died within 8 days of challenge. This study showed for the first time that an H7N9 flu vaccine can protect against this newly emergent influenza subtype, with the added novelty that Inovio's newly created universal "construct" for this subtype was not matched to the virus strain, suggesting the potential to provide protection against other mutated strains that would be expected to emerge within the H7N9 family of influenza. These results also show the speed at which Inovio can construct and test a DNA vaccine against a new virus or new subtype of a virus.